Development and external validation of a composite biomarker-based machine learning model for sarcopenia risk stratification in patients with cardiovascular disease - Takeaways - MDSpire

Development and external validation of a composite biomarker-based machine learning model for sarcopenia risk stratification in patients with cardiovascular disease

  • By

  • Pengcheng Mei

  • Tao Ying

  • Jing Wu

  • Han Wang

  • July 9, 2026

  • 0 min

Share

  • 1

    Sarcopenia is prevalent in patients with cardiovascular disease (CVD) and linked to functional decline and adverse outcomes.

  • 2

    The study identified TyG-BMI as the most informative composite biomarker for sarcopenia risk assessment in CVD patients.

  • 3

    A CatBoost machine learning model incorporating TyG-BMI demonstrated strong discriminative ability for sarcopenia across multiple cohorts.

  • 4

    The Cardiovascular Disease–Sarcopenia Risk Score (CVD-SRS) was derived and validated for consistent risk stratification in diverse populations.

  • 5

    Current sarcopenia diagnostic methods are often impractical in routine cardiovascular practice, highlighting the need for simpler tools.

Original Source(s)

Related Content